Trial intelligence / Profile preview

DIVI: Darbepoetin Plus IV Iron in Preterm Infants

NCT05340465Phase 2

Key facts

Status
Recruiting
Start
Nov 2022
Primary completion
Jan 2027
Countries
1
Sponsor
University of Washington
Modality
Nanoparticles, Erythropoietins, Colony Stimulating Factors
Conditions
preterm birthiron deficiency anemia (IDA)Iron malabsorption
01

Overview

Phase 2, randomised, open-label trial of darbepoetin alfa, iron dextran and ferumoxytol in preterm birth, iron deficiency anemia (IDA) and Iron malabsorption (5 arms), sponsored by University of Washington. Primary endpoints: Plasma Ferritin, Number of IV iron doses required to maintain a ferritin level of > 75 ng/mL and 2 more. Started Nov 2022; status: recruiting.

02

Design

5 arms
Study design
RandomizedOpen-label
  • Group 1. Oral iron

    Oral iron started on day 7 of life, adjusted every 2 weeks.

  • Group 2

    Darbe 10 mcg/kg/week + LMW-ID 10 mg/kg x 1, retreat if ferritin < 76 mcg/L.

  • Group 3

    Darbe 10 mcg/kg/week + LMW-ID 20 mg/kg x 1, retreat if ferritin < 76 mcg/L.

  • Group 4

    Darbe 10 mcg/kg/week + FMX 10 mg/kg x 1, retreat if ferritin < 76 mcg/L.

  • Group 5

    Darbe 10 mcg/kg/week + FMX 20 mg/kg x 1, retreat if ferritin < 76 mcg/L.

03

Who it enrols

Premature infants born at 24 to 31 weeks gestation in the NICU, excluding those with significant fetal/infant anomalies, high iron stores, or active infections.

04

Endpoints

Primary

  • Plasma Ferritin

  • Number of IV iron doses required to maintain a ferritin level of > 75 ng/mL

  • Number of Blood transfusions

  • Volume of blood transfusions

Secondary

  • Number and percent of patients per group that remain transfusion free

  • Hematocrit

  • Safety of IV iron

  • Early gut microbiome comparison between study groups

  • Rate of referral for Brainstem auditory evoked response

  • Rate of pass/fail the General Movements Assessments (GMA)

  • Scores for the Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS)

  • Late gut microbiome comparison between study groups

Beyond the preview

Go deeper on NCT05340465.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05340465.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call